NSF SBIR Phase II Grant Awarded

We are thrilled to announce that we have been awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) in the amount of $984,000. The award will begin in September 2024 and marks a major step forward in our mission to create a diagnostic that enables clinicians to treat bacterial infections in one shift. 

The NSF SBIR program is one of the most competitive non-dilutive funding programs in the country, supporting deep-tech startups developing high-impact, commercially viable innovations. Phase II awards are reserved for companies that successfully demonstrated technical feasibility during Phase I, and they fund the next stage of research and development needed to bring a technology closer to market. 

This award builds on the momentum of our NSF SBIR Phase I grant, received in 2021, which enabled us to demonstrate the feasibility of our approach. The success of that work laid the foundation for Phase II, where we will now develop a regulatory pathway for FDA clearance, develop and characterize antibodies to expand our platform, and validate expanded tests against clinical specimens. 

Receiving back-to-back NSF awards is a meaningful endorsement of both our science and our team. We are deeply grateful to the National Science Foundation for its continued investment, and to our advisors, collaborators, and partners whose contributions have been instrumental at every stage.